滚动资讯
FierceBiotechChutes & Ladders—Helus shuffles out CEO after two months, adds experience to science boardFierceBiotechAfter Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?BioWorldSichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonistsBioWorldShanghai Meiyue Biotech Development presents new molecular glue degradersBioWorldJiangsu Carephar Pharmaceutical describes new AT2 receptor agonistsBioWorldPharma industry faces long haul to get return on investment from AIFierceBiotechAvalyn拟募资1.82亿美元上市，资助改良型呼吸药物三期试验Thermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo FinanceAgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance10x Genomics BlogLiquidCell Dx 任命前 Foundation Medicine、10x Genomics 和 IDT 高管 Mirna Jarosz 为首席执行官；任命前 Foundation Medicine 首席医疗官 Vincent A. Miller 博士为高级战略顾问 - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha
Endpoints News 2025年12月16日

FDA延长对Aldeyra干眼症药物的审批决定。

FDA延长对Aldeyra干眼症药物的审批决定。

原文
暂时没有全文，请查看原始来源。